Exelixis sells cancer drug Cabometyx.
Exelixis, Inc. (EXEL) is expected to report earnings on Tuesday, November 3, 2026, after the close. Estimated release time 16:09 ET. Consensus EPS estimate is $0.89.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-05 | FY2026 Q3 | $0.85 | $0.85 | -0.4% | $628.69M |
| 2026-05-05 | FY2026 Q2 | $0.77 | $0.81 | +5.9% | $610.81M |
| 2026-02-10 | FY2026 Q1 | $0.77 | $0.91 | +18.2% | $598.66M |
| 2025-11-04 | FY2025 Q4 | $0.69 | $0.72 | +5.1% | $597.75M |
| 2025-07-28 | FY2025 Q3 | $0.65 | $0.68 | +4.6% | $568.26M |
| 2025-05-13 | FY2025 Q2 | $0.36 | $0.57 | +59.2% | $555.45M |
| 2025-02-11 | FY2024 Q4 | $0.51 | $0.48 | -5.9% | $566.75M |
| 2024-10-29 | FY2024 Q3 | $0.35 | $0.41 | +17.1% | $539.54M |
EXEL has beaten consensus EPS in 6 of its last 8 reported quarters.
EXEL reported Aug 5. The highlights: EPS of $0.85 — in line with the $0.85 estimate; revenue of $629M — in line with the $636M consensus. Focus now shifts to cabozantinib growth and zanzalintinib.
See EXEL on the live calendar →